The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Open accessAbstract
AIM: To verify the superiority of pemafibrate over placebo and the non-inferiority of pemafibrate to the maximum dose of fenofibrate for determining the percent change in fasting serum triglyceride (TG) levels and to investigate safety by assessing the incidence of adverse events (AEs) and adverse drug reactions (ADRs). METHODS: This phase III, placebo/active drug-controlled, randomized, double-blind, parallel group comparison study enrolled patients with high TG and low high-density lipoprotein cholesterol levels. Patients were randomly assigned to receive placebo; pemafibrate 0.1 mg/day, 0.2 mg/day, or 0.4 mg/day; or fenofibrate 100 mg/day or 200 mg/day for 12 weeks. RESULTS: Among 526 randomized patients, 489 completed the study, with drop-out rates of 0%, 6.7%, 5.5%, 5.9%, 8.2%, and 10.7% in the placebo; pemafibrate 0.1 mg/day, 0.2 mg/day, and 0.4 mg/day; and fenofibrate 100 mg/day and 200 mg/day groups. The study showed the non-inferiority of pemafibrate 0.4 mg/day and 0.2 mg/day to fenofibrate 200 mg/day as well the non-inferiority and superiority of all pemafibrate doses to fenofibrate 100 mg/day for reducing TG levels. No dose-dependent increase in the incidence of AEs or ADRs was observed among the pemafibrate dose groups. The incidence of AEs and ADRs for all pemafibrate doses was similar to that for placebo and fenofibrate 100 mg/day and significantly lower than that for fenofibrate 200 mg/day (P＜0.05). CONCLUSIONS: The favorable safety profile of pemafibrate, with fewer adverse effects on kidney/liver-related laboratory tests and fewer AEs/ADRs, including those leading to treatment discontinuation, over fenofibrate 200 mg/day may justify the use of this novel and potent treatment option for reducing TG levels in a broader range of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When placed in the context of traditional fibrates, pemafibrate’s triglyceride-lowering effects and safety profile appear generally comparable to existing agents.”
From Pemafibrate for hypertriglyceridemia: a meta-analysis of randomized controlled trials evaluating efficacy and safety outcomes (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In head-to-head clinical trials, pemafibrate was observed to reduce triglyceride levels relative to fenofibrate”
From Pemafibrate for hypertriglyceridemia: a meta-analysis of randomized controlled trials evaluating efficacy and safety outcomes (2026) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“and showed similar or slightly greater reductions in some comparisons”
From Pemafibrate for hypertriglyceridemia: a meta-analysis of randomized controlled trials evaluating efficacy and safety outcomes (2026) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“with a generally lower incidence of hepatic and renal adverse events reported in these studies [23, 24]”
From Pemafibrate for hypertriglyceridemia: a meta-analysis of randomized controlled trials evaluating efficacy and safety outcomes (2026) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.029 · Cited by 208
Self-citationBruckert, E., Labreuche, J., Deplanque, D., Touboul, P.-J., & Amarenco, P. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318202709f · Cited by 192
Flagged first, then by citations
1 of the 26 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 25) Hata Y, Goto Y and Itakura H: Clinical assessment of GRS-001 (fenofibrate) in hyperlipidemic patients—a double blind, comparative study, using bezafibrate sustainedrelease tablet as a control drug. Geriatr Med, 1995; 33: 765-822
Cited by
Sorted by citations
Badmus, O. O., Hillhouse, S. A., Anderson, C. D., Hinds, T. D., & Stec, D. E. (2022) · Clinical Science · doi:10.1042/cs20220572 · Cited by 407
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 282
PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C. R., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 260
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191
Self-citationFougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 150
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
Self-citationImpact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 116
Targeting necroptosis in anticancer therapy: mechanisms and modulators
Wu, Y., Dong, G., & Sheng, C. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.007 · Cited by 99
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 84
Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030706 · Cited by 79
Self-citationSascău, R. A., Clément, A., Radu, R., Prisacariu, C., & Stătescu, C. (2021) · Nutrients · doi:10.3390/nu13061774 · Cited by 76
Lipid Lowering Drugs: Present Status and Future Developments
Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00918-3 · Cited by 73
Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements—A Narrative Review
Živković, S., Maric, G. D., Cvetinovic, N., Lepojevic-Stefanovic, D., & Božić, B. (2023) · Nutrients · doi:10.3390/nu15061517 · Cited by 75
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48918 · Cited by 71
Self-citationNovel emerging therapies in atherosclerosis targeting lipid metabolism
Gupta, M., Blumenthal, C., Chatterjee, S., Bandyopadhyay, D., Jain, V., Lavie, C. J., Virani, S. S., Ray, K. K., Aronow, W. S., & Ghosh, R. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1764937 · Cited by 67
Ida, S., Kaneko, R., & Murata, K. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0845-x · Cited by 61
Alexopoulos, A., Qamar, A., Hutchins, K., Crowley, M. J., Batch, B. C., & Guyton, J. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1136-3 · Cited by 62
Benefits and risks of the treatment with fibrates––a comprehensive summary
Okopień, B., Bułdak, Ł., & Bołdys, A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1537780 · Cited by 55
Future perspectives of the pharmacological management of diabetic dyslipidemia
Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 55
Yamashita, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.06.010 · Cited by 51
Self-citationTada, H., Nohara, A., & Kawashiri, M. (2018) · Nutrients · doi:10.3390/nu10111789 · Cited by 53
Ginsberg, H. N., Hounslow, N. J., Senko, Y., Suganami, H., Bogdanski, P., Ceska, R., Kalina, A., Libis, R. A., Supryadkina, T. V., & Hovingh, G. K. (2022) · Diabetes Care · doi:10.2337/dc21-1288 · Cited by 48
Self-citationYamashita, S., Arai, H., Yokote, K., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225537 · Cited by 49
Self-citationTomita, Y., Ozawa, N., Miwa, Y., Ishida, A., Ohta, M., Tsubota, K., & Kurihara, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235878 · Cited by 49
Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13686 · Cited by 46
Self-citationBonilha, I., Zimetti, F., Zanotti, I., Papotti, B., & Sposito, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112233 · Cited by 48
Björnson, E., Packard, C. J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Lundbom, J., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13017 · Cited by 46
Hadjivasilis, A., Kouis, P., Kousios, A., & Panayiotou, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030768 · Cited by 46
Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
Moon, J. H., Kim, K., & Choi, S. H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.402 · Cited by 53
Yokote, K., Yamashita, S., Arai, H., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01291-w · Cited by 48
Self-citationPPARα Agonist Oral Therapy in Diabetic Retinopathy
Tomita, Y., Lee, D., Tsubota, K., & Kurihara, T. (2020) · Biomedicines · doi:10.3390/biomedicines8100433 · Cited by 42
Kasonga, A. E., Kruger, M. C., & Coetzee, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071798 · Cited by 40
Yamashita, S., Rizzo, M., Su, T., & Masuda, D. (2023) · Metabolites · doi:10.3390/metabo13050626 · Cited by 43
Self-citationBiochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis
Joshita, S., Umemura, T., Yamashita, Y., Sugiura, A., Yamazaki, T., Fujimori, N., Matsumoto, A., & Tanaka, E. (2019) · Hepatology Research · doi:10.1111/hepr.13361 · Cited by 38
Sasaki, Y., Raza-Iqbal, S., Tanaka, T., Murakami, K., Anai, M., Osawa, T., Matsumura, Y., Sakai, J., & Kodama, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225682 · Cited by 40
Role of the Gut in Diabetic Dyslipidemia
Stahel, P., Xiao, C., Nahmias, A., & Lewis, G. F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00116 · Cited by 39
Recent advances in synthetic pharmacotherapies for dyslipidaemias
Sirtori, C. R., Yamashita, S., Greco, M. F., Corsini, A., Watts, G. F., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319845314 · Cited by 34
Self-citationTriglycerides and endothelial function: molecular biology to clinical perspective
Kajikawa, M., & Higashi, Y. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000630 · Cited by 29
Drexel, H., Tamargo, J. L., Kaski, J. C., Lewis, B. S., Saely, C. H., Fraunberger, P., Dobrev, D., Komiyama, M., PLATTNER, T., Agewall, S., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad044 · Cited by 32
Kumrić, M., Urlić, H., Božić, J., Vilović, M., Kurir, T. T., Glavaš, D., Miric, D., Zanchi, J., Bradarić, A., Lozo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098062 · Cited by 27
Metabolism in Retinopathy of Prematurity
Tomita, Y., Usui‐Ouchi, A., Nilsson, A., Yang, J., Ko, M., Hellström, A., & Fu, Z. (2021) · Life · doi:10.3390/life11111119 · Cited by 25
Kąpa, M., Koryciarz, I., Kustosik, N., Jurowski, P., & Pniakowska, Z. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030683 · Cited by 25
Genomics of hypertriglyceridemia
Tada, H., Takamura, M., & Kawashiri, M. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.12.005 · Cited by 22
Park, M. S., Youn, J., Kim, E. J., Han, K. H., Lee, S., Kim, S. H., Kim, B. J., Kwon, S. U., & Ryu, K.-H. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.08.005 · Cited by 21
Fenofibrate and Dyslipidemia: Still a Place in Therapy?
Tarantino, N. M., Santoro, F., Correale, M., Gennaro, L. D., Romano, S., Biase, M. D., & Brunetti, N. D. (2018) · Drugs · doi:10.1007/s40265-018-0965-8 · Cited by 21
Wang, Z., Shi, H., Zhao, H., Dong, Z., Zhao, B., Weng, X., Liu, R., Li, X., Hu, K., Zou, Y., et al. (2019) · Current Molecular Medicine · doi:10.2174/1566524019666190207143207 · Cited by 21
Tsui, L., Chen, L., Ye, P., Xu, S., Wu, S., Chen, S. C.-I., & Xie, W. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068915 · Cited by 20
Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection
Gebhardt, A., & Fichtenbaum, C. J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1636033 · Cited by 20
Nakamura, A., Kagaya, Y., Saito, H., Kanazawa, M., Sato, K., Miura, M., Kondo, M., & Endo, H. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63659 · Cited by 18
Medical management of hypertriglyceridemia in pancreatitis
Gligorijevic, N., Stefanović-Račić, M., & Kershaw, E. E. (2023) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000956 · Cited by 20
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Reiner, Ž. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0343 · Cited by 19
Novel Experimental Agents for the Treatment of Hypercholesterolemia
Pećin, I., & Reiner, Ž. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267376 · Cited by 19
Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
Dohmen, K., Onohara, S.-Y., & Harada, S. (2021) · The Korean Journal of Gastroenterology · doi:10.4166/kjg.2021.092 · Cited by 18
Soto, L. G. D. L. P., Gutierrez-Uribe, J. A., Sharma, A. K., & Ramírez‐Jiménez, A. K. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.035 · Cited by 19
Fruchart, J., Hermans, M. P., & Fruchart‐Najib, J. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00860-w · Cited by 18
An Overview of Phytotherapy Used in the Management of Type II Diabetes
Sharma, A. K., Chawla, R., Kaur, J., & Madaan, R. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210617154535 · Cited by 17
Lessons from PROMINENT and prospects for pemafibrate
Fruchart, J.-C., Fruchart-Najib, J., Yamashita, S., Libby, P., Yokote, K., Kodama, T., Tomita, Y., Ridker, P. M., Hermans, M. P., & Zambon, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02305-z · Cited by 16
Self-citationSPPARM alpha: the Lazarus effect
Fruchart, J., & Santos, R. D. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000640 · Cited by 17
Takeda, Y., Sakuma, I., Hiramitsu, S., Okada, M., Ueda, S., & Sakurai, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1094100 · Cited by 15
Yamashita, S., Okazaki, M., Okada, T., Masuda, D., Yokote, K., Arai, H., Araki, E., & Ishibashi, S. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60764 · Cited by 14
Self-citationHow to Handle Elevated Triglycerides: Life after PROMINENT
Pirillo, A., & Catapano, A. L. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01175-2 · Cited by 15
Tanaka, Y., & Kamisako, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166215 · Cited by 14
The Role of Mitochondria in Metabolic Syndrome–Associated Cardiomyopathy
Li, J., Li, J., Chen, Y., Hu, W., Gong, X., Qiu, H., Chen, H., Xin, Y., & Li, H. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9196232 · Cited by 17
Suto, K., Fukuda, D., Shinohara, M., Ganbaatar, B., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., Hirata, K., & Sata, M. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.61101 · Cited by 14
Henry, D., Baugé, E., Hennuyer, N., Ory, K., Derudas, B., Vallez, E., Deprince, A., Lefèbvre, P., Haas, J. T., Staels, B., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adj8192 · Cited by 14
Yamashita, S., Hirano, T., Shimano, H., Tsukamoto, K., Yoshida, M., & Yoshida, H. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14227 · Cited by 14
Self-citationRodríguez‐Gutiérrez, R., González‐González, J. G., Parmar, D., Shaikh, F., & Cruz-López, P. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100233 · Cited by 13
Kim, N. H., Kim, J. Y., Choi, J., & Kim, S. G. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad090 · Cited by 13
Sumida, Y., Toyoda, H., Yasuda, S., Kimoto, S., Sakamoto, K., Nakade, Y., Ito, K., Osonoi, T., & Yoneda, M. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64896 · Cited by 13
Interplay between epigenetic mechanisms and transcription factors in atherosclerosis
Aziz, M., Jandeleit-Dahm, K. A. M., & Khan, A. W. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117615 · Cited by 12
Genetics and regulation of HDL metabolism
Kardassis, D., Thymiakou, E., & Chroni, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159060 · Cited by 12
Tanigawa, R., Nakajima, A., Eguchi, Y., Takahashi, H., Loomba, R. S., Suganami, H., Tanahashi, M., Saito, A., Iida, Y., & Yamashita, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65395 · Cited by 11
Self-citationKhan, M. S., Ghumman, G. M., Baqi, A., Shah, J., Aziz, M., Mir, T., Tahir, A., Katragadda, S., Singh, H., Taleb, M., et al. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00593-6 · Cited by 11
Pemafibrate, a novel selective PPARα modulator, attenuates tamoxifen-induced fatty liver disease
Tanaka, N., Mukaiyama, K., Morikawa, A., Kawakami, S., Ichise, Y., Kimura, T., & Horiuchi, A. (2021) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-021-01386-7 · Cited by 11
Nag, S., Mitra, O., Maturi, B., Kaur, S. P., Saini, A., Nama, M., Roy, S., Samanta, S., Chacko, L., Dutta, R., et al. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100927 · Cited by 12
Dai, W., Lv, Q., Li, Q., Fu, L., Zhang, Y., Zhang, Y., Liu, L., Tanigawa, R., Kunitomi, K., Kamei, R., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64112 · Cited by 9
Self-citationIwaki, M., Kobayashi, T., Nogami, A., Ogawa, Y., Imajo, K., Sakai, E., Nakada, Y., Koyama, S., Kurihashi, T., Oza, N., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-088862 · Cited by 10
Doggrell, S. A. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1609942 · Cited by 11
Seki, M., Nakano, T., Tanaka, S., Matsukuma, Y., Funakoshi, K., Ohkuma, T., & Kitazono, T. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02322-4 · Cited by 8
Arai, H., Yamashita, S., Araki, E., Yokote, K., Tanigawa, R., Saito, A., Yamasaki, S., Suganami, H., & Ishibashi, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64677 · Cited by 8
Self-citationIntegrative Multiomics Approaches for Discovery of New Drug Targets for Cardiovascular Disease
Reilly, M. P., & Bornfeldt, K. (2021) · Circulation · doi:10.1161/circulationaha.121.054900 · Cited by 8
Beyond lipids: fenofibrate in diabetic retinopathy and nephropathy
Liu, M., Lim, S. T., Song, W., Coffman, T. M., & Wang, X. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.07.014 · Cited by 7
Selective activation of PPARα maintains thermogenic capacity of beige adipocytes
Egusa, G., Ohno, H., Nagano, G., Sagawa, J., Shinjo, H., Yamamoto, Y., Himeno, N., Morita, Y., Kanai, A., Baba, R., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107143 · Cited by 9
Hirano, T., Hayashi, T., Sugita, H., Tamasawa, A., Goto, S., Tomoyasu, M., Yamamoto, T., Ohara, M., Terasaki, M., Kushima, H., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14076 · Cited by 8
Komatsu, T., Miura, T., Joko, K., Sunohara, D., Mochidome, T., Kasai, T., & Ikeda, U. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6871-20 · Cited by 6
Fibrates: A Possible Treatment Option for Patients with Abdominal Aortic Aneurysm?
Amioka, N., & Miyoshi, T. (2022) · Biomolecules · doi:10.3390/biom12010074 · Cited by 6
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Arai, H., Yamashita, S., Araki, E., Yokote, K., Tanigawa, R., Saito, A., Furukawa, D., Suganami, H., & Ishibashi, S. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65350 · Cited by 5
Self-citationNeurological complications of cardiovascular drugs
Kelly, M. A. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819814-8.00020-2 · Cited by 5
Takeda, Y., Sakuma, I., Hiramitsu, S., Okada, M., Ueda, S., & Sakurai, M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061360 · Cited by 4
Bando, H., Taneda, S., & Manda, N. (2021) · JMA Journal · doi:10.31662/jmaj.2020-0104 · Cited by 5
Fibrates : Do They Still Have a Role in Therapy in 2025?
Pirillo, A., Zambon, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01379-8 · Cited by 4
Ooba, N., Takahashi, M., Nagamura, M., Ushida, M., Kawakami, E., Kimura, M., Sato, T., Takahashi, Y., Tokuyoshi, J., Hashiba, H., et al. (2022) · Current Drug Safety · doi:10.2174/1574886317666220224142511 · Cited by 4
Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio
Imamura, T., Narang, N., & Kinugawa, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102820 · Cited by 5
Wang, X., Luo, J., Lu, Z., Fang, S., Sun, M., Luo, W., Shen, J., Liu, A., & Ye, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190458 · Cited by 6
Hida, Y., Imamura, T., & Kinugawa, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216915 · Cited by 5
Is there still a place for fenofibrate-statin combination therapy?
Farnier, M., Vrablı́k, M., & Catapano, A. L. (2023) · European Atherosclerosis Journal · doi:10.56095/eaj.v2i3.55 · Cited by 4
Kamimura, T., Hounslow, N. J., Suganami, H., & Tanigawa, R. (2024) · Clinical and Translational Science · doi:10.1111/cts.13900 · Cited by 4
Self-citationTreatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline
Xu, J., & Ashjian, E. J. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211053489 · Cited by 4
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
Metadata
- Authors
- Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., Ishibashi, S., & on behalf of the K-877 Study Group
- Affiliations
- National Center for Geriatrics and Gerontology (JP)
- Rinku General Medical Center (JP)
- Chiba University (JP)
- Kumamoto University (JP)
- Kowa (Japan) (JP)
- Jichi Medical University (JP)
- Corresponding author
- Arai, Hidenori
- Venue
- Journal of Atherosclerosis and Thrombosis
- Publisher
- Japan Atherosclerosis Society
- Published
- 2018-06-01
- Volume
- 25
- Issue
- 6
- Pages
- 521-538
- ISSN
- 1340-3478 (ISSN-L)
- 1880-3873
- PMC
- PMC6005227
- OpenAlex
- W2796005123
- Cited by
- 136
- References
- 26
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 16 · 2023: 21 · 2022: 14 · 2021: 22 · 2020: 9 · 2019: 22 · 2018: 7
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Journal of Atherosclerosis and Thrombosis (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Kowa Company
- Japan Society for the Promotion of Science (17H04201, 18K08482)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- pemafibrate, fenofibrate, hypertriglyceridemia, low HDL cholesterol, triglyceride lowering, non-inferiority, adverse drug reactions, drug safety, fibrates, dose comparison
- MeSH terms
- Hypolipidemic Agents, Benzoxazoles, Butyrates, Double-Blind Method, Female, Follow-Up Studies, Humans, Cholesterol, HDL, Male, Middle Aged, Fenofibrate, Prognosis, Triglycerides, Hypertriglyceridemia, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
